Timo Soeterik

130 CHAPTER 7 TABLE 5. Systematic analysis of outcomes for model 2 per threshold using all three cohorts Threshold (%) Below the cut-off (Nerve sparing recommended) Above the cut-off (Nerve sparing not recommended) Total (%) Without EPE (%) With EPE (%) Total (%) Without EPE (%) With EPE (%) 5 256 (7) 251 (98) 5 (2) 3484 (93) 2657 (76) 827 (24) 7.5 922 (17) 883 (96) 39 (4) 2818 (83) 2025 (72) 793 (28) 10 1141 (31) 1082 (95) 59 (5) 2599 (69) 1826 (70) 773 (30) 12.5 1346 (36) 1271 (94) 75 (6) 2394 (64) 1637 (68) 757 (32) 15 1612 (43) 1497 (93) 115 (7) 2128 (57) 1411 (66) 717 (34) 17.5 2044 (55) 1876 (92) 168 (8) 1696 (45) 1032 (61) 664 (39) 20 2170 (58) 1980 (91) 190 (9) 1570 (42) 928 (59) 642 (41) 22.5 2235 (60) 2035 (91) 200 (9) 1505 (40) 873 (58) 632 (42) 25 2306 (62) 2085 (90) 221 (10) 1434 (38) 823 (57) 611 (43) 27.5 2508 (67) 2250 (90) 258 (10) 1232 (33) 658 (53) 574 (47) 30 2692 (72) 2379 (88) 313 (12) 1048 (28) 529 (50) 519 (50) FIGURE 3. Net benefit of model 2 determined in all three cohorts using decision curve analysis A. Development B. Validation C. Validation 2